Literature DB >> 34362452

Correction to: Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.

Faroogh Marofi1, Safa Tahmasebi2, Heshu Sulaiman Rahman3, Denis Kaigorodov4, Alexander Markov5, Alexei Valerievich Yumashev6, Navid Shomali7,8, Max Stanley Chartrand9, Yashwant Pathak10,11, Rebar N Mohammed12, Mostafa Jarahian13, Roza Motavalli14, Farhad Motavalli Khiavi15.   

Abstract

Entities:  

Year:  2021        PMID： 34362452     DOI： 10.1186/s13287-021-02523-2

Source DB:  PubMed          Journal:  Stem Cell Res Ther        ISSN： 1757-6512            Impact factor:   6.832


× No keyword cloud information.
  1 in total

Review 1.  Any closer to successful therapy of multiple myeloma? CAR-T cell is a good reason for optimism.

Authors:  Faroogh Marofi; Safa Tahmasebi; Heshu Sulaiman Rahman; Denis Kaigorodov; Alexander Markov; Alexei Valerievich Yumashev; Navid Shomali; Max Stanley Chartrand; Yashwant Pathak; Rebar N Mohammed; Mostafa Jarahian; Roza Motavalli; Farhad Motavalli Khiavi
Journal:  Stem Cell Res Ther       Date:  2021-03-29       Impact factor: 6.832
  1 in total
  2 in total

Review 1.  CRISPR/Cas9 application in cancer therapy: a pioneering genome editing tool.

Authors:  Roozbeh Moghaddar; Amirhossein Fakhre Yaseri; Sadegh Shojaei Baghini; Zhanna R Gardanova; Saeme Azizi Hassan Abadi; Burhan Abdullah Zaman; Ahmet İlhan; Navid Shomali; Ali Adili
Journal:  Cell Mol Biol Lett       Date:  2022-05-04       Impact factor: 8.702

Review 2.  Potential of chimeric antigen receptor (CAR)-redirected immune cells in breast cancer therapies: Recent advances.

Authors:  Marzieh Nikoo; Mohammad Rudiansyah; Dmitry Olegovich Bokov; Nurlan T Jainakbaev; Wanich Suksatan; Mohammad Javed Ansari; Lakshmi Thangavelu; Supat Chupradit; Amir Zamani; Ali Adili; Navid Shomali; Morteza Akbari
Journal:  J Cell Mol Med       Date:  2022-06-28       Impact factor: 5.295
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.